Live Breaking News & Updates on Daniel vasella

Stay informed with the latest breaking news from Daniel vasella on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Daniel vasella and stay connected to the pulse of your community

Interview mit Daniel Vasella – «Dass es eine Rezession geben wird, ist nicht schlecht»

Der Ex-Novartis-Chef hat ein dickes Fell. Im Gespräch erklärt er, warum er nach seinem Abschied trotzdem untergetaucht ist, er eine Rezession für nötig hält und Manager mehr über Sex reden müssen.

China , United-states , Russia , Switzerland , Zugersee , Switzerland-general- , American , Daniel-vasella , Vasella-aabach , Miriam-kappeler , Herr-vasella , Glaxosmithkline

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

ImmunOs Therapeutics Raises $74 Million Series B Financing Round
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Zurich , Züsz , Switzerland , United-states , Daniel-vasella , Shelley-chu , Reinhard-ambros , Ludger-wess-ines-regina-buth , Marcos-milla , Markus-hosang , Seanr-smith , Michael-baran

ImmunOs Therapeutics Raises $74M in Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Zurich , Züsz , Switzerland , Daniel-vasella , Shelley-chu , Reinhard-ambros , Markus-hosang , Marcos-milla , Seanr-smith , Michael-baran , Andreas-jurgeit , Schroder-adveq

Focus On - Switzerland, Ophthalmics, Management

Focus On - Switzerland, Ophthalmics, Management
thepharmaletter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thepharmaletter.com Daily Mail and Mail on Sunday newspapers.

Germany , Switzerland , German , Swiss , Daniel-vasella , Levi-garraway , Joanne-chang , Sandra-horning , Pureos-bioventures , Novartis , Casebia-therapeutics ,

Eclipsebio Raises $14M in Series A Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Phoenix , Arizona , United-states , San-diego , California , Alexandria , Al-iskandariyah , Egypt , Daniel-vasella , Hallie-kuhn , Peter-chu , Alexandria-real-estate-equities-inc

mPharma raises $35million in round participated by Tinder co-founder's JAM fund, Bharti executive – TechCrunch

Ghanaian health tech startup mPharma is building a network of community pharmacies across Africa as it plans to be the go-to primary healthcare service provider for millions of people residing in the region. mPharma plans to grow its community (Mutti) pharmacies across eight markets in Africa to be the first point of care for patients. […]

Kenya , Malawi , Nigeria , Ghana , Rwanda , Gabon , Zambia , Uganda , Ethiopia , Ghanaian , Daniel-vasella , Daniel-shoukimas

Roche and Novartis part ways with share purchase

Roche and Novartis part ways with share purchase
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Switzerland , Swiss , Daniel-vasella , Christoph-franz , Novartis , Hoffman-la-roche ,

Novartis Unwinds Roche Ties With $20.7 Billion Stake Sale

(Bloomberg) -- Novartis AG agreed to sell its stake in Roche Holding AG back to the rival Swiss drugmaker for $20.7 billion, ending a two-decade investment and building up a cash pile for possible acquisitions. Novartis took advantage of record levels in Roche’s voting stock to unwind the remnants of a failed takeover attempt that began in 2001 under then-Novartis Chief Executive Officer Daniel Vasella. The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring and drugmakers need funds to develop new treatments. CEO Vas Narasimhan has been working to prune and reshape Novartis since taking over in 2018. Novartis will use the money according to its capital priorities, spokesman Richard Jarvis said Thursday. In order, those are investing in the existing business, adding to the dividend, acquisitions and share buybacks. The deal will let Roche’s founding Hoffmann-La Roche family consolidate control at a price that represents a 13% discount to the last close for the company’s voting shares. The price for the transaction is 356.93 francs ($391) for each voting share. Novartis rose as much as 2.2% Thursday in Zurich. Roche voting shares gained as much as 2.5% to 421.80 francs. “The deal is positive for Roche and lifts the possible overhang from the risk of pursuing larger acquisitions,” Peter Welford, an analyst at Jefferies, wrote in a note titled “Ending the Marriage.” It also simplifies Novartis’s structure and will inevitably spark a debate about which biotechs it may now target for acquisitions, he said. In September, Novartis approached Roche about selling the stake, spokesmen at both companies said. For Novartis, the deal was attractive because Roche was willing to buy back the whole stake in a single transaction, allowing a clean exit, spokesman Jarvis said. The drugmaker views it as shedding a non-strategic asset, he added. Novartis owns 33% of Roche’s voting shares, and Novartis has made a 10% annual gain on them over the past two decades. The gap between Roche bearer shares reached a 10-year high against non-voting shares in September. Roche plans to cancel the shares. The company has a dual-class shareholding structure, with voting and non-voting shares. The founding Hoffmann-La Roche family will see their portion of the voting stock rise from just over half to about 67.5%. The percentage held by the public will increase from 16.6% to 24.9%. Family members won’t participate in the purchase, and Roche said they didn’t take part in decision-making or vote on the deal. Last week, Narasimhan announced he’s exploring options for Novartis’s generic-drugs unit Sandoz, which has suffered from eroding prices and tough competition. Both companies are based in Basel, Switzerland. (Updates with analyst comment in sixth paragraph. A previous version of this story was corrected to show Novartis approached Roche about the deal) ©2021 Bloomberg L.P.

Switzerland , Swiss , Richard-jarvis , Daniel-vasella , Bloomberg , Glaxosmithkline-plc , Roche-holding , Novartis , Hoffmann-la-roche , Executive-officer-vas-narasimhan , Business-general- ,

Novartis to sell long-held stake in Roche for nearly $21B

BioPharma

Switzerland , Swiss , Daniel-vasella , Novarti-zolgensma , Joseph-jimenez , Roche-ocrevus , Novarti-kesimpta , Glaxosmithkline , Novartis , Dive-brief , That-novartis , Innovative-medicines

Novartis is cashing out of Roche for $21B, 20 years after mega-merger that never happened

Novartis’s equity stake in Roche, shares acquired 20 years ago in a strategy to build up to a potential mega-merger, will be sold back to the company in a $20.7 billion deal. The cash proceeds could fuel Novartis R&D, as well as potential dealmaking.

Switzerland , Swiss , Daniel-vasella , Pfizer , Glaxosmithkline , Medicines-company , Novartis , Financial-times , Hoffman-la-roche , Novartis-gene , Financial-time , Weight-loss